Haleon plc (HLN) stock analysis

In our weekly check, Haleon plc is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 22 pass, warnings: 3, red flags: 0.

About Haleon plc

Haleon plc is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in the United Kingdom, listed on NYSE as HLN.

What our checks show for HLN

Warning signs

• Analysts expect only about 3.7% a year of growth in revenue.
• Revenue grew only 0.5% a year over the last 3 years.
• Return on capital (ROCE) is only 9%.

Strengths

• Operating profit covers interest 9.7 times over.
• The gross margin is 63.3% and has risen by 1 points: pricing power is holding.
• Operating cash flow is 1.4x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 11.1% a year over the next years.
• Analysts expect the net margin to improve by 3.3 points from today's 14.8%.
• Earnings per share grew 14.5% a year over the last 3 years.

Similar companies

TEVA · ZTS · TAK · VTRS · ELAN · ALKS

Questions

What grade does Haleon plc (HLN) have?

In our weekly check, Haleon plc is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 22 pass, warnings: 3, red flags: 0. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of HLN stock?

This week's biggest flags for Haleon plc: Weak revenue forecast, Weak revenue growth, Low return on capital. In total 3 of 25 checks show a warning or a red flag.

What does Haleon plc do?

Haleon plc is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in the United Kingdom, listed on NYSE as HLN.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis